Related Experiment Videos
Early-phase events with the mitroflow pericardial valve
L B McGrath1, L Gonzalez-Lavin
1Department of Surgery, Deborah Heart and Lung Center, and the Deborah Research Institute, Browns Mills, New Jersey, USA.
Texas Heart Institute Journal
|January 1, 1988
Summary
The Mitroflow pericardial valve shows early promise with a low risk of valve-related complications and satisfactory implantation. Further follow-up is needed to assess long-term outcomes in cardiac surgery patients.
Area of Science:
- Cardiovascular Surgery
- Biomaterials Science
Background:
- The Mitroflow pericardial valve is a prosthetic device used in cardiac valve replacement surgery.
- Assessing the early performance and safety of new prosthetic valves is crucial for patient outcomes.
Purpose of the Study:
- To evaluate the early clinical performance and safety of the Mitroflow pericardial valve.
- To identify risk factors associated with hospital mortality after Mitroflow valve implantation.
Main Methods:
- A retrospective analysis of 116 Mitroflow pericardial valve implantations in 98 patients between January 1986 and January 1987.
- Follow-up of hospital survivors for 6 to 13 months to assess late complications, survival rates, and functional status.
Main Results:
- Hospital mortality was 10%, with higher functional class and longer cardiopulmonary bypass time as risk factors.
- Actuarial survival at 15 months was 87%. No reoperations or cases of hemolysis or endocarditis were reported.
- Two late deaths occurred, unrelated to the valve itself. Mild mitral incompetence was noted in one patient.
Conclusions:
- The Mitroflow pericardial valve demonstrates a low risk of early valve-related events and is technically satisfactory for implantation.
- Patients showed improved functional class post-surgery. Long-term follow-up is essential to fully determine the valve's efficacy and safety profile.